{"References": [{"title": "Genetic Modifiers of Sickle Cell Disease", "authors": "Steinberg MH, Sebastiani P", "journal": "American Journal of Hematology", "year": "2012", "volumes": "87", "first page": "795", "last page": "803", "DOI": "10.1002/ajh.23232"}, {"title": "Gene Therapy in Sickle Cell Disease: Promises and Challenges", "authors": "Esrick EB, Bauer DE", "journal": "Hematology/Oncology Clinics of North America", "year": "2020", "volumes": "34", "first page": "537", "last page": "551", "DOI": "10.1016/j.hoc.2020.02.005"}, {"title": "Gene Editing for Sickle Cell Disease: Opportunities and Challenges", "authors": "Hoban MD, Orkin SH, Bauer DE", "journal": "Blood", "year": "2016", "volumes": "127", "first page": "839", "last page": "848", "DOI": "10.1182/blood-2015-09-618736"}, {"title": "Viral Vectors for Gene Therapy: Applications in Sickle Cell Disease", "authors": "Naldini L", "journal": "Nature Reviews Genetics", "year": "2015", "volumes": "16", "first page": "311", "last page": "320", "DOI": "10.1038/nrg3921"}, {"title": "Genotoxicity of Gene Therapy Vectors: Current Challenges and Future Directions", "authors": "Hacein-Bey-Abina S, Von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M", "journal": "Nature Medicine", "year": "2003", "volumes": "9", "first page": "367", "last page": "369", "DOI": "10.1038/nm0403-367"}, {"title": "Advances in Gene Therapy for Sickle Cell Disease", "authors": "Kanter J, Walters MC", "journal": "Discovery Medicine", "year": "2015", "volumes": "19", "first page": "461", "last page": "469", "DOI": "10.1007/s11899-015-0275-4"}, {"title": "CRISPR/Cas9 Gene Editing for Sickle Cell Disease: Progress and Challenges", "authors": "Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, Pavel-Dinu M, Saxena N, Wilkens AB, Mantri S", "journal": "Science Translational Medicine", "year": "2016", "volumes": "8", "first page": "360ra134", "last page": "360ra134", "DOI": "10.1126/scitranslmed.aaf9336"}, {"title": "Gene Therapy for Sickle Cell Disease: A Review of the Current Landscape", "authors": "Tisdale JF, Dunbar CE", "journal": "Hematology", "year": "2015", "volumes": "2015", "first page": "287", "last page": "293", "DOI": "10.1182/asheducation-2015.1.287"}, {"title": "The Role of Genetic Modifiers in Sickle Cell Disease", "authors": "Lettre G", "journal": "Hematology/Oncology Clinics of North America", "year": "2010", "volumes": "24", "first page": "517", "last page": "528", "DOI": "10.1016/j.hoc.2010.02.002"}, {"title": "Gene Therapy for Sickle Cell Disease: An Update", "authors": "Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, Caccavelli L, Neven B, Bourget P, El Nemer W", "journal": "Blood", "year": "2017", "volumes": "129", "first page": "266", "last page": "274", "DOI": "10.1182/blood-2016-09-737981"}]}